Urinary tract infections (UTIs) in men, though less frequent than in women, represent a significant clinical challenge due to their increasing incidence with age and distinct microbiological profiles. This expert review analyzed data of urine cultures in men with community-acquired UTIs, collected from emergency departments of 15 french hospitals, from the private laboratory group Atoutbio (21 sites in Meurthe-et-Moselle and the Vosges French departments, alongside primary care records from the AntibioClic tool and the PRIMO database, to characterize the bacterial epidemiology of community-acquired male UTIs in France. Escherichia coli (39–40%) dominated, followed by Enterococcus faecalis (13–15%), Klebsiella pneumoniae (6–8%), and Proteus mirabilis (5–6%). Resistance rates were as follows amoxicillin (47–53.5%), amoxicillin-clavulanate (24–35.7%), trimethoprim-sulfamethoxazole (25.4–31.5%), and fluoroquinolones (16.3–20.2%). Resistance to third-generation cephalosporins (6.6–9.3%) and mecillinam (6.8–8.9%) was lower, while fosfomycin (1.4–1.5%) and nitrofurantoin (0.4–0.7%) retained high susceptibility. Extended-spectrum β-lactamase (ESBL)-producing E. coli ranged from 2 to 8.4%, with carbapenemase producers remaining rare (0.1%). Resistance was higher in men > 65 years, particularly in nursing homes, where 3GC resistance reached 15–18%. « Emerging uropathogens » ( Aerococcus urinae 1–1.1%, Actinotignum schaalii 0.1–0.4%) were rare. This study highlights the greater microbial diversity in male UTIs compared to women and underscores the need for systematic urine culture, susceptibility testing, and empirical therapy tailored to resistance patterns, age, and risk factors.